An adaptive strategy for assessing regional consistency in multiregional clinical trials

被引:10
|
作者
Chen, Joshua [1 ]
Quan, Hui [2 ]
Gallo, Paul [3 ]
Ouyang, Soo P. [4 ]
Binkowitz, Bruce [1 ]
机构
[1] Merck Res Labs, Rahway, NJ 07026 USA
[2] Sanofi Aventis, Bridgewater, NJ USA
[3] Novartis, E Hanover, NJ USA
[4] Celgene, Summit, NJ USA
关键词
COVARIATE ADJUSTMENT; DESIGN;
D O I
10.1177/1740774512440635
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Unexpected regional difference in treatment effect has been reported in recent multiregional clinical trials (MRCTs). This may cause difficulty in interpreting results and can have regulatory implications such as marketing approvals and/or product labels in various markets. Careful consideration of consistency across regions and appropriate plans to address potential regional difference are necessary at the design stage. However, assessment of consistency in treatment effect is generally not the primary objective, and therefore, when there is no strong a priori reason to expect a regional difference, a MRCT is not usually designed to address the regional consistency. Unexpected regional finding may arise and increase the risk of ambiguous or controversial results at the end of the study. Purpose To mitigate this risk, we propose an adaptive strategy for regional assessment based upon accumulated blinded data. Methods If review of accumulated blinded data shows unexpectedly severe imbalance in an intrinsic or extrinsic factor, and further assessment indicates that this factor could be a potential effect modifier as supported by biological plausibility or blinded correlation analysis, a stratified regional analysis controlled for this factor may be specified and documented before database lock. Results The proposed adaptive strategy can help with the interpretation of unexpected regional finding. A recent trial is used to illustrate the approach. Limitations Even if the imbalanced factor may appear to explain away the regional difference, establishment of causal effect is usually difficult and requires more involved effort. Conclusions This approach, by prespecifying the stratified analysis, can reduce the risk of post hoc exaggerated emphases across many possible exploratory analyses and provide greater confidence in the validity of the conclusions. If a causal effect can be established that the apparent regional difference is likely caused by this intrinsic or extrinsic factor, this prespecified analysis can also help guide clinical practice.
引用
收藏
页码:330 / 339
页数:10
相关论文
共 50 条
  • [1] Regional consistency assessment in multiregional clinical trials
    Li, Gang
    Quan, Hui
    Wang, Yining
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2024,
  • [2] Cautionary note on regional consistency evaluation in multiregional clinical trials with binary outcomes
    Homma, Gosuke
    [J]. PHARMACEUTICAL STATISTICS, 2024, 23 (03) : 385 - 398
  • [3] QUALITATIVE CONSISTENCY OF TREATMENT EFFECTS IN MULTIREGIONAL CLINICAL TRIALS
    Tanaka, Yoko
    Li, Gang
    Wang, Yining
    Chen, Josh
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2012, 22 (05) : 988 - 1000
  • [4] Assessment of Consistency of Treatment Effects in Multiregional Clinical Trials
    Quan, Hui
    Li, Mingyu
    Chen, Joshua
    Gallo, Paul
    Binkowitz, Bruce
    Ibia, Ekopimo
    Tanaka, Yoko
    Ouyang, Soo Peter
    Luo, Xiaolong
    Li, Gang
    Menjoge, Shailendra
    Talerico, Steven
    Ikeda, Kimitoshi
    [J]. DRUG INFORMATION JOURNAL, 2010, 44 (05): : 617 - 632
  • [5] Assessment of Consistency of Treatment Effects in Multiregional Clinical Trials
    Hui Quan
    Mingyu Li
    Joshua Chen
    Paul Gallo
    Bruce Binkowitz
    Ekapimo Ibia
    Yoko Tanaka
    Soo Peter Ouyang
    Xiaolong Luo
    Gang Li
    Shailendra Menjoge
    Steven Talerico
    Kimitoshi Ikeda
    [J]. Drug information journal : DIJ / Drug Information Association, 2010, 44 (5): : 617 - 632
  • [6] Assessing the consistency of the treatment effect under the discrete random effects model in multiregional clinical trials
    Liu, Jung-Tzu
    Tsou, Hsiao-Hui
    Lan, K. K. Gordon
    Chen, Chi-Tian
    Lai, Yi-Hsuan
    Chang, Wan-Jung
    Tzeng, Chyng-Shyan
    Hsiao, Chin-Fu
    [J]. STATISTICS IN MEDICINE, 2016, 35 (14) : 2301 - 2314
  • [7] Potential Factors Influencing Regional Differences and Similarities in Multiregional Clinical Trials
    Ohishi, Masahiko
    [J]. DRUG INFORMATION JOURNAL, 2012, 46 (05): : 565 - 572
  • [8] Unified additional requirement in consideration of regional approval for multiregional clinical trials
    Teng, Zhaoyang
    Chen, Yeh-Fong
    Chang, Mark
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2017, 27 (06) : 903 - 917
  • [9] Potential Factors Influencing Regional Differences and Similarities in Multiregional Clinical Trials
    Masahiko Ohishi
    [J]. Drug information journal : DIJ / Drug Information Association, 2012, 46 : 565 - 572
  • [10] DESIGN AND ANALYSIS ISSUES OF MULTIREGIONAL CLINICAL TRIALS WITH DIFFERENT REGIONAL PRIMARY ENDPOINTS
    Tsou, Hsiao-Hui
    Tsong, Yi
    Chang, Wan-Jung
    Dong, Xiaoyu
    Hsiao, Chin-Fu
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2012, 22 (05) : 1051 - 1059